Location [1]
Protein [2]
Retinoic acid receptor alpha
Synonyms [1]

RARA (Retinoic acid receptor, alpha) is a gene that encodes for a nuclear retinoic acid receptor, a transcription regulating protein (Gene 2013b). In cancer, rearrangements involving RARA have been observed in AML and APL. Its role is also being investigated in gastric and other cancers.


RARA is altered in 0.70% of all cancers with breast invasive ductal carcinoma, esophageal adenocarcinoma, adenocarcinoma of the gastroesophageal junction, invasive breast carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].

RARA GENIE Cases - Top Diseases

The most common alterations in RARA are RARA Amplification (0.75%) and RARA Loss (0.04%) [3].

RARA GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of RARA in Diseases

Acute Promyelocytic Leukemia +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Chronic Lymphocytic Leukemia +

Chronic Myelomonocytic Leukemia +

Refractory Anemia With Excess Blasts +

Acute Lymphoblastic Leukemia +

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative +

Mantle Cell Lymphoma +

Myelodysplastic/Myeloproliferative Neoplasm +

Myeloproliferative Neoplasm +

Refractory Anemia With Excess Blasts-1 +

Refractory Anemia With Excess Blasts-2 +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.